secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2022-06-23T23:59:59+00:00
Accession:  0001493152-22-017562
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Provectus shareholders approve reverse stock split, elect directors at annual meeting
--------------------------------------------------------------------------------

- All five director nominees elected: Bailey, Horowitz, Lacey, Pershing, Rodrigues; 102.4M broker non-votes.
- Advisory say-on-pay approved with 206.7M for vs 9.6M against.
- Ratification of Marcum LLP as auditor for 2022 passed with 313.4M for.
- Authorization to implement reverse stock split (1:10 to 1:50) approved with 300.5M for.
- Authorization to reduce authorized shares proportionally to reverse split ratio approved with 302.5M for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315222017562/0001493152-22-017562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315222017562/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-017562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer